Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Core Insights - Apogee Therapeutics, Inc. has successfully closed a public offering of 8,048,782 shares of common stock, raising approximately $345 million before expenses [1] Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized, novel biologics for the inflammatory and immunology markets, targeting conditions such as Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and Chronic Obstructive Pulmonary Disease [5] - The company's lead program, APG777, is aimed at treating Atopic Dermatitis, which is identified as a significant and under-penetrated market [5] - Apogee's antibody programs are designed to enhance existing therapies by targeting established mechanisms of action and utilizing advanced antibody engineering to improve properties like half-life [5]